Advertisement
IDXX vs SNN
Which Stock Would AI Choose? IDEXX Laboratories (IDXX) vs. Smith & Nephew (SNN) Stock Comparison
Key Takeaways
- IDXX is a dominant, high-margin player in veterinary diagnostics with faster growth, but trades at a premium valuation and faces softer U.S. veterinary visit trends.
- SNN is a diversified medical technology company executing a turnaround, with improving profitability but a reduced revenue-growth outlook driven by U.S. orthopaedics and wound-care headwinds.
- IDXX raised its full-year earnings guidance on recurring diagnostics strength, while SNN cut its revenue outlook yet preserved profit, cash-flow, and return targets.
- Relative performance diverges: IDXX has pulled back sharply year to date despite solid fundamentals, while SNN has been supported by margin expansion and capital returns.
- This stock comparison highlights a trade-off between higher-growth quality (IDXX) and a value-oriented restructuring story (SNN).
Introduction
Investors evaluating healthcare opportunities often weigh high-growth franchises against restructuring plays. IDXX, IDEXX Laboratories, dominates companion-animal veterinary diagnostics, while SNN, Smith & Nephew, is a U.K.-based medical technology company focused on orthopaedics, sports medicine, and advanced wound management. Although both operate in the broader healthcare sector, their business models, growth drivers, and risk profiles differ substantially. This comparison is relevant for traders and investors assessing relative performance, market positioning, and whether momentum or stability currently offers a more compelling setup.
IDXX Overview and Recent Performance
IDEXX Laboratories is a leading provider of diagnostics, software, and imaging for the veterinary market, complemented by water and livestock testing businesses. Recent market activity has highlighted robust execution despite a softer demand backdrop. In its latest reported quarter, IDXX delivered revenue of roughly $1.22 billion, up about 10% year over year, with recurring companion-animal diagnostics revenue growing double digits organically. The company also raised its full-year earnings outlook to a range of $14.69 to $14.94 per share, reflecting expanding margins and increased diagnostic utilization.
Sentiment has been mixed, however. U.S. veterinary traffic has remained soft, with same-store clinical visits declining modestly and wellness visits under pressure, even as higher testing intensity and innovation platforms such as inVue Dx and Cancer Dx have offset some of the volume weakness. The stock has declined sharply year to date, which has reset its valuation but also reflects ongoing concern about durable demand. Relative performance has lagged the broader market in recent weeks.
SNN Overview and Recent Performance
Smith & Nephew is a global medical technology company operating across orthopaedics, sports medicine and ear, nose, and throat (ENT), and advanced wound management. Recent performance reflects a company balancing portfolio momentum with targeted turnaround efforts. In its latest reported quarter, SNN posted revenue of about $1.6 billion, with underlying growth of roughly 1.6%, as strength in sports medicine and ENT was offset by weakness in U.S. orthopaedics and advanced wound bioactives.
Management lowered its full-year underlying revenue-growth outlook to around 4% from roughly 6%, while affirming targets for trading profit growth, free cash flow, and return on invested capital (ROIC). Profitability improved, with trading margin expanding and efficiency savings running ahead of plan. The company continues to return capital through dividends and a buyback, and its sports medicine franchise has delivered double-digit growth in key products. Overall, the equity has been characterized by improving margins and shareholder returns, tempered by softness in its U.S. joint-replacement and skin-substitute businesses.
Trending AI Robots
For investors seeking a more systematic approach to relative strength and market positioning, Tickeron offers hundreds of AI Trading Bots that trade thousands of different tickers. Because not every bot fits every market environment, Tickeron curates only the most suitable strategies into its Trending AI Robots section. These bots span a wide range of trading styles, strategies, timeframes, performance statistics, and sets of tickers, giving traders flexibility to match their objectives and risk tolerance. The curated list helps users identify strategies that have demonstrated consistency under current conditions rather than relying on a one-size-fits-all approach. Explore the Trending AI Robots page to review the available strategies and performance data.
Head-to-Head Comparison
The two companies differ most in growth profile and valuation. IDXX benefits from recurring, consumable-driven revenue and a dominant installed base, supporting double-digit earnings growth and a premium forward price-to-earnings multiple. Its key risk is soft veterinary visit trends, which could pressure reference-laboratory volumes if wellness activity remains weak. By contrast, SNN is positioned as a value story with margin expansion, efficiency savings, and capital returns, but faces company-specific challenges in U.S. knee implants and reimbursement-driven pressure in skin substitutes.
In terms of market positioning, IDXX has narrower but highly predictable end-market exposure, while SNN is more diversified across surgical and wound-care categories with greater geographic balance. Momentum has favored SNN's improving profitability narrative, whereas IDXX has experienced a valuation reset despite solid fundamentals. Risk factors also diverge: IDXX is sensitive to veterinary clinic volumes and premium valuation, while SNN faces portfolio gaps and payer-related headwinds. The trade-off is essentially quality growth versus restructuring-driven stability.
Tickeron AI Verdict
Based on observable trend consistency, earnings momentum, and relative positioning, Tickeron's AI would likely favor IDXX for its more durable recurring-revenue model, expanding margins, and raised guidance, which provide a clearer and more consistent growth signal. That said, the AI framework weighs momentum and valuation as well, and SNN's improving profitability and capital-return profile offer a contrasting stability case. The verdict remains probabilistic rather than definitive: IDXX's higher-quality earnings growth currently presents a stronger fundamental trajectory, though its recent price weakness and premium multiple introduce near-term uncertainty that a diversified or more defensive allocation might offset with SNN.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IDXX is a StrongBuy and SNN is a StrongBuy.
Momentum Indicator for IDXX turns positive, indicating new upward trend
IDXX saw its Momentum Indicator move above the 0 level on October 14, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 93 similar instances where the indicator turned positive. In 56 of the 93 cases, the stock moved higher in the following days. The odds of a move higher are at 60%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for IDXX just turned positive on September 22, 2026. Looking at past instances where IDXX's MACD turned positive, the stock continued to rise in 19 of 41 cases over the following month. The odds of a continued upward trend are 46%.
IDXX moved above its 50-day moving average on October 15, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for IDXX crossed bullishly above the 50-day moving average on October 21, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 22 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 59%.
Following a +5.93% 3-day Advance, the price is estimated to grow further. Considering data from situations where IDXX advanced for three days, in 174 of 289 cases, the price rose further within the following month. The odds of a continued upward trend are 60%.
Bearish Trend Analysis
The RSI Indicator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 6 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IDXX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 69%.
IDXX broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for IDXX entered a downward trend on September 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 2 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 16 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 49 (best 1 - 100 worst), indicating fairly steady price growth. IDXX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 71 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 81 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (27.689) is normal, around the industry mean (66.046). P/E Ratio (39.606) is within average values for comparable stocks, (2.422). Projected Growth (PEG Ratio) (2.894) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (9.042) is also within normal values, averaging (9.775).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IDXX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 89, placing this stock worse than average.
SNN's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for SNN turned positive on October 05, 2026. Looking at past instances where SNN's MACD turned positive, the stock continued to rise in 32 of 50 cases over the following month. The odds of a continued upward trend are 64%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 07, 2026. You may want to consider a long position or call options on SNN as a result. In 48 of 83 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 58%.
SNN moved above its 50-day moving average on October 15, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for SNN crossed bullishly above the 50-day moving average on October 20, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 59%.
Following a +4.42% 3-day Advance, the price is estimated to grow further. Considering data from situations where SNN advanced for three days, in 192 of 333 cases, the price rose further within the following month. The odds of a continued upward trend are 58%.
Bearish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 10 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SNN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 57%.
SNN broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for SNN entered a downward trend on October 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 15 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.495) is normal, around the industry mean (2.874). P/E Ratio (20.809) is within average values for comparable stocks, (2.324). Projected Growth (PEG Ratio) (1.035) is also within normal values, averaging (11.052). Dividend Yield (0.039) settles around the average of (0.009) among similar stocks. P/S Ratio (1.905) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 56 (best 1 - 100 worst), indicating steady price growth. SNN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 83 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 92 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SNN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
IDXX | SNN | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 32 | 39 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 81 Overvalued | 15 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 16 | 92 | |
PRICE GROWTH RATING 1..100 | 49 | 56 | |
P/E GROWTH RATING 1..100 | 71 | 83 | |
SEASONALITY SCORE 1..100 | 2 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
SNN's Valuation (15) in the Medical Specialties industry is significantly better than the same rating for IDXX (81). This means that SNN’s stock grew significantly faster than IDXX’s over the last 12 months.
SNN's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as IDXX (100). This means that SNN’s stock grew similarly to IDXX’s over the last 12 months.
IDXX's SMR Rating (16) in the Medical Specialties industry is significantly better than the same rating for SNN (92). This means that IDXX’s stock grew significantly faster than SNN’s over the last 12 months.
IDXX's Price Growth Rating (49) in the Medical Specialties industry is in the same range as SNN (56). This means that IDXX’s stock grew similarly to SNN’s over the last 12 months.
IDXX's P/E Growth Rating (71) in the Medical Specialties industry is in the same range as SNN (83). This means that IDXX’s stock grew similarly to SNN’s over the last 12 months.
| IDXX | SNN | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 73% | 2 days ago 47% |
| Stochastic ODDS (%) | 2 days ago 74% | 2 days ago 49% |
| Momentum ODDS (%) | 2 days ago 60% | 2 days ago 58% |
| MACD ODDS (%) | 2 days ago 46% | 2 days ago 64% |
| TrendWeek ODDS (%) | 2 days ago 61% | 2 days ago 56% |
| TrendMonth ODDS (%) | 2 days ago 53% | 2 days ago 58% |
| Advances ODDS (%) | 8 days ago 60% | 9 days ago 58% |
| Declines ODDS (%) | 17 days ago 69% | 5 days ago 57% |
| BollingerBands ODDS (%) | 2 days ago 77% | 2 days ago 62% |
| Aroon ODDS (%) | 2 days ago 68% | 2 days ago 58% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
IDXX’s FA Score shows that 1 FA rating(s) are green while SNN’s FA Score has 1 green FA rating(s).
- IDXX’s FA Score: 1 green, 4 red.
- SNN’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
IDXX’s TA Score shows that 5 TA indicator(s) are bullish while SNN’s TA Score has 5 bullish TA indicator(s).
- IDXX’s TA Score: 5 bullish, 5 bearish.
- SNN’s TA Score: 5 bullish, 5 bearish.
Price Growth
IDXX (@Medical Specialties) experienced а +3.58% price change this week, while SNN (@Medical/Nursing Services) price change was +6.15% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was +1.54%. For the same industry, the average monthly price growth was -5.91%, and the average quarterly price growth was +42.02%.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -0.53%. For the same industry, the average monthly price growth was -9.75%, and the average quarterly price growth was -10.71%.
Reported Earning Dates
IDXX is expected to report earnings on Nov 02, 2026.
SNN is expected to report earnings on Nov 04, 2026.
Industries' Descriptions
@Medical Specialties (+1.54% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
@Medical/Nursing Services (-0.53% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
Advertisement